1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Vimta Labs Limited

Vimta Labs Limited

VIMTALABS.NS
Vimta Labs LimitedIN flagNational Stock Exchange of India
566.10
INR
+7.20
- -
25.29BMarket Cap
Vimta Labs Limited
VIMTALABS.NS
(National Stock Exchange of India)

Recent

price

566.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
21.64
19.75
24.68
26.76
24.26
28.2
34.79
40.84
47.03
40.35
47.17
62.41
71.19
65.14
77.5
91.44
91.44
Revenue per Share
-1.06
-3.48
0.95
2.99
1.14
1.46
2.4
3.72
5.72
1.55
4.84
9.35
10.88
9.26
15.17
17.4
17.4
Basic EPS, GAAP
1.14
2.05
2.62
1.84
1.74
-3.78
-3.61
2.05
5.11
1.93
0.93
4.6
8.62
-3.54
3.28
10.63
- -
Free Cash Flow per Basic Share
0.47
0.23
- -
0.35
1.17
0.6
0.6
- -
1.21
1.21
- -
1
1
1
1
1
- -
Dividend per Share
9.49
6.01
6.52
8.04
8.36
9.07
11.46
15.18
19.7
20.04
24.88
33.23
43.08
50.04
64.13
81.31
81.31
Book Value per Share
28.24
24.77
25.38
27.23
27.67
28.52
30.79
34.39
38.8
37.84
42.7
48.64
59.65
68.85
83.91
101.47
101.47
Tangible Book Value per Share
44
44
44
44
44
44
44
44
44
44
44
44
44
44
44
45
45
Basic Weighted Avg Shares
957
873
1,091
1,183
1,073
1,247
1,538
1,806
2,080
1,784
2,086
2,759
3,151
2,886
3,440
4,073
4,073
Sales/Revenue/Turnover
0.57
-12.88
8.47
14.88
8.26
7.82
12.66
18.51
21.96
6.08
17.27
22.97
22.12
22.34
26.34
26.2
24
Operating Margin (%)
165
159
150
94
111
103
96
157
197
209
231
233
307
342
357
438
438
Depreciation Expense
-47
-154
42
132
51
64
106
164
253
68
214
413
482
410
673
775
775
Net Income, GAAP
- -
- -
3.69
25.04
23.76
22.96
35.94
35.72
27.97
17.23
25
25.78
25.89
21.91
24.99
25.44
25.44
Effective Tax Rate (%)
-4.87
-17.6
3.86
11.19
4.72
5.16
6.88
9.1
12.17
3.84
10.26
14.98
15.29
14.21
19.58
19.03
19.03
Profit Margin (%)
38
-34
165
267
359
411
104
337
490
383
566
766
1,064
1,035
1,234
1,593
1,593
Working Capital
20
- -
- -
- -
- -
160
181
195
116
54
142
127
99
91
32
16
16
LT Debt
1,250
1,096
1,123
1,204
1,223
1,261
1,361
1,521
1,716
1,729
1,944
2,340
2,818
3,141
3,788
4,569
4,569
Total Equity
- -
- -
7.04
10.49
5.32
5.39
7.51
11.56
17.02
4.52
12.79
20.18
19.3
16.43
19.32
19.06
17.46
Return on Invested Capital (%)
- -
- -
13.32
32.86
13.03
13.29
14.54
19.17
25.04
7.56
17.31
27.35
26.27
18.9
25.61
23.65
23.8
Return on Capital (%)
-10.41
-44.88
15.21
41.15
13.96
16.7
23.34
27.9
32.83
7.79
21.55
32.17
28.54
19.89
26.6
23.97
23.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
49
- -
18
LT Borrowings
19
- -
16
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
- -
45
Market Capitalization
31,474
26,951
16,957

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,128
- -
2,249
Cash, Cash Equivalents & STI
565
- -
669
Accounts Receivable, Net
1,071
- -
1,057
Inventories
286
- -
299
Total Current Liabilities
645
- -
655
Payables & Accruals
- -
- -
- -
ST Debt
49
- -
18
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.92%
18.7%
20.6%
Free Cash Flow
24.92%
75.13%
225.15%
Net Income, GAAP
48.76%
34.82%
15.1%
Sales/Revenue/Turnover
13.43%
15.13%
18.4%
Total Cash Common Dividend
- -
- -
0.38%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
835
655
746
797
2,886
2025
749
847
899
944
3,440
2026
976
1,018
986
1,092
4,073

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.76
1.43
2.28
- -
9.26
2025
2.77
3.44
4.83
4.11
15.17
2026
4.25
4.46
3.96
4.73
17.4

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
Similar Companies
Global Cord Blood Corporation (CO)
WuXi AppTec Co., Ltd. (WUXAY)
Sonic Healthcare Limited (SKHCF)
Euroespes, S.A. (EEP.MC)
PharmChem, Inc. (PCHM)
Metropolis Healthcare Limited (METROPOLIS.NS)
Business
Vimta Labs Limited, founded in 1984 and headquartered in Hyderabad, India, operates as a leading contract research and testing organization primarily serving the pharmaceutical, biopharmaceutical, medical device, agrochemical, food, environmental, and electronics industries. The company offers a comprehensive range of services including drug discovery and development support, preclinical research, clinical research, cGMP and non-GMP analytical services, bioanalytical services, stability studies, microbiological testing, environmental monitoring, and regulatory compliance services. Vimta Labs also provides specialized testing solutions for food and beverages, water, electronic and electrical products (EMI/EMC testing), and environmental impact assessments. Recent strategic changes include the divestment of its diagnostic and pathological services business to Thyrocare Technologies Limited in a transaction completed in 2024 to sharpen focus on its core contract research and testing services and enhance operational efficiency. The business transfer agreement allowed Thyrocare to expand its diagnostics footprint in southern India, while Vimta Labs concentrated on strengthening its contract research offerings and regulatory services. Vimta Labs has also expanded its employee stock option plan in 2025 and its shareholding structure saw the transfer of promoter shares from Andhra Pradesh Industrial Development Corporation Limited to Telangana State Industrial Development Corporation Limited. The company operates extensively across India with its labs in Telangana and regional presences supporting global clients in pharmaceuticals, agriculture, environmental sectors, and specialty industries. Vimta Labs maintains strategic partnerships and long-term customer engagement through dedicated contract labs designed for ongoing collaborations with clients using full-time equivalent staffing models. The company's integrated service portfolio combined with recent operational streamlining positions it as a prominent scientific, technical, and regulatory partner in the Indian and international contract research and testing markets.